April 15, 2025
Life value
STELLAPHARM was born to care and protect patient’s health, to help enhancing their lives and living longer. Your health, for today and for future.
SIEMENS BUYS US FIRM DOTMATICS FOR $5.1 BN IN AI SOFTWARE PUSH
Germany group Siemens said on Wednesday it is buying Dotmatics, a US software company, for $5.1 billion to leverage its use of artificial intelligence to make drug discoveries.
Siemens said the acquisition was “complementary” to its expansion into Life Sciences and would lift its game in a market needing more medication innovation as populations age.
“These trends underscore the need for digital transformation, with software spending expected to double over the next five years,” Siemens said in a statement.
The German group said that it expected Docmatics to be immediately profitable, and to bring in $100 million a year in revenue over the mid-term, rising to $500 million in the long-term.
It said the transaction would be completed in the first half of next year.
Siemens recently bought another US software firm also using AI, Altair Engineering, for $10 billion.
Docmatics, founded in 2005 and with a workforce of 800 people, presents itself as a leader in R&D software, and has a platform using AI to accelerate drug research.
Siemens, Germany’s second-biggest company by market capitalisation, has been seeing increased revenues from its software division as its digital products for factories face a slump.
Source: Vietnam Investment Review
About STELLAPHARM
Stellapharm J.V. Co., Ltd. is currently known as one of leading generics pharmaceutical companies and strong manufacturers in Vietnam. Established in 2000, Stellapharm was built on the foundation of a manufacturing factory in Vietnam and formed a joint venture with a partner from Germany. We focus on both prescription drugs and non-prescription especially in cardiovascular diseases, anti-diabetics drugs, etc. Products of Stellapharm are now used by millions of patients in more than 50 countries worldwide.
The company is globally recognized for its quality through our facilities have been audited and approved by stringent authority like EMA, PMDA, Taiwan GMP, local WHO and others.
Additional information for this article: Stellapharm J.V. Co., Ltd. – Branch 1
A: 40 Tu Do Avenue, Vietnam – Singapore Industrial Park, An Phu Ward, Thuan An City, Binh Duong Province, Vietnam
T: +84 274 376 7470 | F: +84 274 376 7469 | E: info@stellapharm.com | W: www.stellapharm.com
You May like
24
Mar 2025
CHINESE DRUG MAKER AKESO HAILED AS BIOTECH’S ‘DEEPSEEK MOMENT’ AMID US COMPETITION
Akeso’s immunotherapy drug allowed half of its patients to go 11.1 months without their condition worsening Chinese drug maker Akeso, whose new cancer drug has outperformed a leading Western peer in clinical studies, is being hailed as the “DeepSeek moment” for China’s drug industry, as biotech emerges as a new front in the escalating US-China
19
Mar 2025
GOOGLE PLANS TO RELEASE NEW ‘OPEN’ AI MODELS FOR DRUG DISCOVERY
During a health-focused event in New York on Tuesday, Google announced that it’s developing a collection of “open” AI models for drug discovery called TxGemma. The AI models, which Google said will be released through its Health AI Developer Foundations program later this month, can understand both “regular text” and the structures of different “therapeutic
18
Dec 2023
BIG PHARMA BETS ON AI (ARTIFICIAL INTELLIGENCE) TO SPEED UP CLINICAL TRIALS
Major drugmakers are using artificial intelligence to find patients for clinical trials quickly, or to reduce the number of people needed to test medicines, both accelerating drug development and potentially saving millions of dollars. Human studies are the most expensive and time-consuming part of drug development as it can take years to recruit patients and